Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析

◆英語タイトル:Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15776
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:78
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Eli Lilly and Co (LLY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline products. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

Mar 28,2019 Lilly and ImmuNext enter autoimmune disease research alliance
Mar 20,2019 NCCN announces six quality improvement projects in Gastric Cancer care approved for collaboration with Lilly Oncology
Mar 04,2019 Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price
Feb 18,2019 Lilly closes $8bn Loxo Oncology acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Eli Lilly and Co – Key Facts
Eli Lilly and Co – Key Employees
Eli Lilly and Co – Key Employee Biographies
Eli Lilly and Co – Major Products and Services
Eli Lilly and Co – History
Eli Lilly and Co – Company Statement
Eli Lilly and Co – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Eli Lilly and Co – Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Human Pharmaceuticals
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other Foreign Countries
Performance
Geographical Segment: United States
Performance
R&D Overview
Eli Lilly and Co – Corporate Strategy
Eli Lilly and Co – SWOT Analysis
SWOT Analysis – Overview
Eli Lilly and Co – Strengths
Eli Lilly and Co – Weaknesses
Eli Lilly and Co – Opportunities
Eli Lilly and Co – Threats
Eli Lilly and Co – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eli Lilly and Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 28, 2019: Lilly and ImmuNext enter autoimmune disease research alliance
Mar 20, 2019: NCCN announces six quality improvement projects in Gastric Cancer care approved for collaboration with Lilly Oncology
Mar 04, 2019: Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price
Feb 18, 2019: Lilly closes $8bn Loxo Oncology acquisition
Feb 15, 2019: Bayer gains full rights to TRK inhibitors Vitrakvi, LOXO-195 as Eli Lilly completes Loxo Oncology deal
Feb 15, 2019: Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices
Feb 13, 2019: Drugs targeting metastatic cancers, opioid addiction are among additional specialty drugs available through AllianceRx Walgreens Prime
Feb 06, 2019: Lilly reports strong fourth-quarter and full-year 2018 financial results, lowers 2019 EPS guidance to reflect the pending acquisition of loxo oncology
Jan 31, 2019: Sanofi, Lilly and Novo face enquiry over high insulin prices in US
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Eli Lilly and Co, Key Facts
Eli Lilly and Co, Key Employees
Eli Lilly and Co, Key Employee Biographies
Eli Lilly and Co, Major Products and Services
Eli Lilly and Co, History
Eli Lilly and Co, Subsidiaries
Eli Lilly and Co, Joint Venture
Eli Lilly and Co, Key Competitors
Eli Lilly and Co, Ratios based on current share price
Eli Lilly and Co, Annual Ratios
Eli Lilly and Co, Annual Ratios (Cont...1)
Eli Lilly and Co, Annual Ratios (Cont...2)
Eli Lilly and Co, Interim Ratios
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eli Lilly and Co, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Eli Lilly and Co, Performance Chart (2014 - 2018)
Eli Lilly and Co, Ratio Charts
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Volkswind GmbH:電力:M&Aディール及び事業提携情報
    Summary Volkswind GmbH (Volkswind) a subsidiary of Axpo Holding AG, is an independent renewable power producer. It undertakes the planning, development, construction and operations of wind power plants. Volkswind builds wind farms with wind turbines from various suppliers including Seimens, Enercon, …
  • Goodwin Biotechnology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Goodwin Biotechnology Inc (GBI), a subsidiary of Wallace Pharmaceuticals Pvt Ltd, is a biological contract development and manufacturing organization that offers antibody drug conjugates, radioimmunoconjugates, and other protein bioconjugates. The organization offers cell culture, purificati …
  • Epcor Utilities Inc:企業の発電所・SWOT分析2018
    Epcor Utilities Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • FedEx Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' FedEx Corporation Mergers and A …
  • Mecom Group plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Mecom Group plc Mergers and Acq …
  • Nan Tsan Co., Ltd. (4712):企業概要、財務及び戦略的SWOT分析
    Summary Nan Tsan Co., Ltd. (Nan Tsan) is a chemical product manufacturing company. The company produces coloring agents. Its products include aquatic biotech, organic agriculture and pigment business. Nan Tsan’s aquatic biotech provides aquatic farming and breeding processes. Its aquatic biotechnolo …
  • CH2M HILL Companies, Ltd.:企業の戦略・SWOT・財務情報
    CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bemis Company Inc (BMS):企業の財務・戦略的SWOT分析
    Bemis Company Inc (BMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Carena, Inc.(製薬・医療分野):企業M&A動向
    Summary Carena Inc. (Carena) is a telemedicine solution provider. The company serves patients via phone, Webcam, or house call to diagnose and treat injuries and illness. It offers virtual house call and in-home care services integrated with other company-sponsored health and productivity initiative …
  • Gilat Satellite Networks, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Gilat Satellite Networks, Ltd. …
  • Astea International, Inc. (ATEA):企業財務及び戦略的SWOT分析
    Summary Astea International, Inc. (Astea) is an information technology company that offers end-to-end service management software solutions. The company offers products which include Astea Alliance and FieldCentrix. It provides field services, contract and warranty management, mobile workforce manag …
  • DTE Energy Company:企業の戦略・SWOT・財務情報
    DTE Energy Company - Strategy, SWOT and Corporate Finance Report Summary DTE Energy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AmerisourceBergen Corporation (ABC):企業のM&A・提携動向(医療機器分野)
    Summary AmerisourceBergen Corporation (AmerisourceBergen) is a pharmaceutical services provider. The company is one of the largest global pharmaceutical sourcing and distribution services companies. It offers a wide range of services ranging from drug distribution to manufacturer solutions including …
  • iNova Pharmaceuticals (Australia) Pty Limited:企業の戦略的SWOT分析
    iNova Pharmaceuticals (Australia) Pty Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Bigpoint GmbH:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Bigpoint GmbH Mergers and Acqui …
  • Unum Therapeutics Inc:企業のM&A・提携動向(医療分野)
    Summary Unum Therapeutics Inc (Unum) is a cellular therapeutics company that discovers, develops, and commercializes novel antibody-coupled cellular immunotherapies. Its lead program, ATTCK20 is combined with ACTR anti-CD20 and used for the treatment of leukemia and lymphoma. The company uses its pr …
  • Coeur Mining, Inc:企業のM&A・事業提携・投資動向
    Coeur Mining, Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Coeur Mining, Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Pan Orient Energy Corp. (POE):企業の財務及び戦略的SWOT分析
    Summary Pan Orient Energy Corp. (POE) is an oil and natural gas company that explores and produces the oil and gas in Asia. The company’s principal properties are divided into three distinct groups, which include partially developed concessions located on-shore Thailand, interests in production shar …
  • Seven Bank, Ltd.:企業の戦略・SWOT・財務情報
    Seven Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PUMA SE:企業の戦略・SWOT・財務分析
    SummaryPUMA SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - Deta …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆